MK-2870-005 MK-2870 Monotherapy Versus Treatment of Physician's Choice in Endometrial Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is an option for patients with endometrial cancer. We want to know how well it works compared to standard chemotherapy.

What is the Condition Being Studied?

Advanced Endometrial Cancer

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with endometrial carcinoma or carcinosarcoma
Have received previous treatment with platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy (given either together or separately)
Are not pregnant or breastfeeding

For more information about who can join this study, contact the study team at william.s.andrews@duke.edu.

What is Involved?

If you choose to join this study, you will get a random assignment (like a coin flip) to either take the study drug or a combination of doxorubicin and paclitaxel (the standard chemotherapy regimen).

If you are assigned the study drug, you will get a dose of it every 2 weeks.
If you are assigned to get standard chemotherapy, you will get a dose of doxorubicin once every 3 weeks. You will also get paclitaxel once per week for 3 out of 4 weeks.

You will continue to receive your assigned study drug regimen as long as you benefit from it. You may be in the study for up to 4 years.

Study Details

Full Title

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG- 3095)

Principal Investigator